ストックスクリーナーアプリを入手
9.51
1.06%
0.10
プレマーケット:
9.77
0.26
+2.73%
前日終値:
$9.41
開ける：
$9.5
24時間の取引高:
1.75M
Relative Volume:
0.70
時価総額：
$2.84B
収益：
$493.67M
当期純損益:
$-104.69M
株価収益率:
-27.97
EPS:
-0.34
ネットキャッシュフロー:
$-31.51M
1週間 パフォーマンス:
+3.26%
1か月 パフォーマンス:
-2.96%
6か月 パフォーマンス:
-8.38%
1年 パフォーマンス:
-20.95%
1日の値動き範囲:
$9.395
$9.63
1週間の範囲:
$9.115
$9.63
52週間の値動き範囲:
$8.785
$14.03
Amicus Therapeutics Inc Stock (FOLD) Company Profile
名前
Amicus Therapeutics Inc
セクター
電話
(609) 662-2000
住所
47 HULFISH STREET, PRINCETON, NJ
FOLD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
9.51 | 2.84B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 開始されました | Jefferies | Buy |
| 2024-05-30 | 開始されました | Wells Fargo | Overweight |
| 2024-05-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 再開されました | Goldman | Neutral |
| 2022-01-14 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | アップグレード | Stifel | Hold → Buy |
| 2021-09-30 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 再開されました | BTIG Research | Buy |
| 2021-05-27 | 開始されました | Needham | Hold |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 開始されました | Stifel | Hold |
| 2021-02-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-02-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-06-05 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 開始されました | Janney | Buy |
| 2019-01-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 開始されました | Citigroup | Neutral |
| 2018-08-17 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
| 2017-09-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-08-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-01-24 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 開始されました | BofA/Merrill | Buy |
| 2016-04-14 | 開始されました | Robert W. Baird | Neutral |
| 2016-04-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2015-09-16 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Amicus Therapeutics Inc (FOLD) 最新ニュース
Leerink Partnrs Issues Optimistic Outlook for FOLD Earnings - MarketBeat
Q2 Earnings Forecast for FOLD Issued By Leerink Partnrs - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Is Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Amicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside Potential - Yahoo Finance
Jefferies Initiates Coverage of Amicus Therapeutics (FOLD) with Buy Recommendation - MSN
Cantor Fitzgerald Reaffirms Overweight Rating for Amicus Therapeutics (NASDAQ:FOLD) - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Enzyme Replacement Therapy Market Deep Research Report with - openPR
When (FOLD) Moves Investors should Listen - Stock Traders Daily
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $16.88 - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook - MSN
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpStill a Buy? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Earns Hold Rating from Needham & Company LLC - MarketBeat
Amicus Therapeutics expects 2024 revenue slightly above consensus, guides 2025 - MSN
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts - Benzinga
Shareholders in Amicus Therapeutics (NASDAQ:FOLD) have lost 32%, as stock drops 3.0% this past week - Yahoo Finance
Fabry Disease Treatment Market Top Companies StudySanofi SA, - openPR
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook - GlobeNewswire
Amicus Therapeutics Reports Stellar 32% Revenue Growth to $528.5M, Eyes $1B Sales Target - StockTitan
Is Amicus Therapeutics (FOLD) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Amicus Therapeutics stock hits 52-week low at $9.01 By Investing.com - Investing.com Canada
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year LowShould You Sell? - MarketBeat
Amicus Therapeutics stock hits 52-week low at $9.01 - Investing.com
Principal Financial Group Inc. Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Principal Financial Group Inc. - MarketBeat
How the (FOLD) price action is used to our Advantage - Stock Traders Daily
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Amicus Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
JPMorgan Chase & Co. Sells 1,984,751 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Trimmed by JPMorgan Chase & Co. - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Update - MarketBeat
Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues - Simply Wall St
Amicus Therapeutics: Cheap Heading Into 2025 (NASDAQ:FOLD) - Seeking Alpha
Stifel Financial Corp Sells 21,615 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Geode Capital Management LLC Acquires 80,926 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Fabry Disease Treatment Market Growth in Future Scope 2024-2031 - openPR
FOLD: 3 High-Growth Biotech Stocks to Watch - StockNews.com
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to "Hold" at StockNews.com - MarketBeat
Y Intercept Hong Kong Ltd Has $374,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Up 5.2%Time to Buy? - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lessened by Orion Portfolio Solutions LLC - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down – Here’s What Happened - Defense World
Amicus Therapeutics Inc (FOLD) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):